Comparison 1. Cranberry products versus placebo/control.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Participants with one or more UTIs at follow‐up	13	2462	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.71, 1.04]
1.1 Women with recurrent UTIs	4	594	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.42, 1.31]
1.2 Elderly men and women	2	413	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.39, 1.44]
1.3 People with neuropathic bladder/spinal injuries	2	353	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.75, 1.20]
1.4 Pregnant women	2	674	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.93, 1.17]
1.5 Children	2	309	Risk Ratio (M‐H, Random, 95% CI)	0.48 [0.19, 1.22]
1.6 Radiotherapy patients	1	119	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.75, 1.77]
2 Adverse effects	4		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Stomach burn and general weakness	1	34	Risk Ratio (M‐H, Random, 95% CI)	0.13 [0.01, 2.46]
2.2 Vomitting	1	37	Risk Ratio (M‐H, Random, 95% CI)	6.0 [0.33, 108.56]
2.3 Nausea	2	187	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.23, 3.94]
2.4 Diarrhoea	1	37	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.06, 12.59]
2.5 Gastroenteritis	2	413	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.10, 1.96]
2.6 Any gastrointestinal effect	4	597	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.31, 2.27]